Launch of Insilico Medicine’s R&D center in AI and quantum computing in Abu Dhabi
Abu Dhabi, 01 Feb. 10, 2023 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), a clinical-stage artificial intelligence (AI)-focused drug discovery company, today announces the opening of the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the largest AI-powered biotechnology research center in the region.
Located at the headquarters of the International Renewable Energy Agency (IRENA) in Masdar City, the flagship of Abu Dhabi’s sustainable urban development, the research and development (R&D) center will include global talent in artificial intelligence and technology development. software dedicated to expanding Insilico’s end-to-end capabilities. AI-driven drug discovery platform, Pharma.AI, exploring research on aging and sustainable chemistry, and supporting the digital transformation of healthcare in the region.
The inauguration took place in the atrium of IRENA’s headquarters in Masdar City, attended by nearly 100 ecosystem partners from government, academia, the investment community and the industry. AI and biotechnology. The event included speeches by HE Omar Al Olama, Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico , and Alex Aliper, Ph.D., President of Insilico.
“The prime location, strong and stable economy, developed infrastructure and highly skilled talent make Abu Dhabi an emerging hub that attracts high-tech companies from all over the world. We are thrilled to be part of that,” said Alex Aliper, Ph.D., President of Insilico, who will take on the role of general manager of the regional hub. “We plan to hire locally and work closely with biotech companies and academic partners to license Insilico’s proprietary software and collaborate on joint research projects to facilitate the digital transformation of the industry. local health care.”
“This is exactly the kind of breakthrough work in artificial intelligence that we aim to support in our Free Zone and innovation ecosystem,” said Ahmed Baghoum, the acting CEO of Masdar City. “We are delighted with this important milestone for Insilico Medicine, especially as it takes place during the Year of Sustainable Development. We look forward to the transformational research that is sure to come out of this incredible new hub, and we thank the Abu Dhabi Investment Office for attracting these kinds of organizations to Masdar City.
Insilico has made steady inroads in the Middle East. On January 31, 2023, the company announced that it would receive support from the Abu Dhabi Investment Office (ADIO) to establish its regional headquarters in Abu Dhabi focused on R&D for its AI platform. Eng. Abdulla Abdul Aziz AlShamsi, Acting Managing Director of the Abu Dhabi Investment Office, said: “ADIO congratulates Insilico Medicine on the opening of a regional headquarters in the capital of the United Arab Emirates. Abu Dhabi has made it a priority to advance technological solutions that drive economic progress in the region and beyond. Insilico Medicine is a prime example of the success of this strategy and proof of the limitless opportunities available to health technology companies in Abu Dhabi.
In August 2022, the company announced a Series D2 investment led by Prosperity7 Ventures, Aramco Ventures’ diversified growth fund, expanding its AI biotechnology expertise in Saudi Arabia. The company has also signed a memorandum of understanding with Saudi Arabia’s Ministry of Investment, which includes providing Insilico’s end-to-end AI drug discovery platform to local biotech companies, in partnership with local biotechnologies on robotic drug discovery, contributing local expertise in clinical trials. , and further develop projects that extend a healthy and productive longevity.
Insilico Founder and CEO Alex Zhavoronkov, Ph.D., was also a guest speaker at the Global AI Summit in Riyadh, Saudi Arabia in September 2022, an event focused on AI for Good. humanity.
“Since our inception, our mission has been to extend healthy, productive longevity for everyone on the planet. Over the past decade, we have developed a platform for drug discovery and longevity and become the “one of the leading companies in this field. Now we would like to expand our global infrastructure to the Middle East”, said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. “We look forward to expanding our presence and relationships in the region by establishing a true AI drug discovery center in Abu Dhabi.”
About Insilico Medicine
Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-based drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) and age-related diseases.
More information on www.insilico.com
For media inquiries, please contact media@insilicomedicine.com
Enclosed
CONTACT: Brita Belli Insilico Medicine 475-225-0843 brita@insilico.com
